



ASX: SPL
US OTC: SPHRY

Starpharma Announces Collaboration and License Agreement with Genentech

Shareholder Presentation
22 September 2025

Executive Summary

- Starpharma has signed a collaboration and license agreement with Genentech, a member of the Roche Group.
- Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.
- Starpharma will receive an upfront payment of USD \$5.5 million (~AUD \$8.3 million).
- Starpharma is eligible to receive up to USD \$564 million (~AUD \$855 million) in success-based development, regulatory, and commercial milestones.
- In addition to this amount, Starpharma is eligible for tiered royalties on global net sales of products resulting from the collaboration.

About Starpharma

Starpharma is an Australian biotechnology company with over 20 years of experience in advancing dendrimer technology from the lab to the patient



Clinically validated DEP® platform technology

More than 350 patients treated with DEP® across multiple clinical oncology programs.



Leadership in dendrimer science and drug development

20 years of dendrimer innovation, science & pharmaceutical development.



Broad technology application

Versatile and scalable technology, supporting applications in oncology, radiotheranostics, and more.



Strategic global partnerships

High-impact partnerships with global leaders, leveraging Starpharma's DEP® platform to expand commercial opportunities.

About Genentech

Considered the founder of the biotech industry and now a member of the Roche Group, Genentech has been delivering on the promise of biotechnology for nearly 50 years



Pioneering pharmaceutical innovation

Discovered the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.



A community of changemakers

Nearly 50 years of working to solve unmet medical needs. Staff of 11.9K people.



Partnering to solve complex health challenges

250+ ongoing collaborations around the world.



Strong product pipeline

Around 70 new investigational medicines in clinical development and over 270 active clinical trials in the United States.

Collaboration Overview



Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.



Genentech has an exclusive worldwide license under Starpharma's IP to commercialize products resulting from the parties' collaboration.



Genentech will be responsible for all development and commercialization of products resulting from the collaboration, which could include multiple products for each target.

Financial Terms

Upfront payment
USD \$5.5 million
(~AUD \$8.3 million)




Success-based milestones
Up to USD \$564 million
(~AUD \$855 million)



Starpharma is also eligible for tiered royalties on global net sales of products resulting from the collaboration.

Strategic Significance for Starpharma



Recognises the potential of Starpharma's dendrimer technology in drug delivery innovation



Demonstrates the opportunities presented by research partnerships



Marks important progress against our strategic plan



Thank you.

Investor Hub

investors.starpharma.com

Corporate Office

4 – 6 Southampton Crescent
Abbotsford, Victoria 3067
Australia

